Rhumbline Advisers Purchases 39,229 Shares of Moderna, Inc. $MRNA

Rhumbline Advisers lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 6.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 662,086 shares of the company’s stock after acquiring an additional 39,229 shares during the quarter. Rhumbline Advisers owned approximately 0.17% of Moderna worth $17,102,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Rothschild Investment LLC grew its holdings in shares of Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after purchasing an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in Moderna during the 2nd quarter worth about $26,000. MUFG Securities EMEA plc bought a new stake in Moderna during the 2nd quarter worth about $28,000. Whittier Trust Co. bought a new stake in Moderna during the 2nd quarter worth about $28,000. Finally, Assetmark Inc. increased its position in Moderna by 137.7% in the 2nd quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock valued at $36,000 after acquiring an additional 752 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares in the company, valued at approximately $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research reports. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research report on Monday, December 1st. Citigroup restated a “neutral” rating on shares of Moderna in a research report on Monday. Royal Bank Of Canada increased their price objective on Moderna from $25.00 to $30.00 and gave the company a “sector perform” rating in a research report on Tuesday. Barclays began coverage on Moderna in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $25.00 target price for the company. Finally, Morgan Stanley set a $30.00 price target on Moderna in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of “Reduce” and a consensus price target of $31.47.

Moderna Stock Up 4.0%

NASDAQ:MRNA opened at $43.93 on Wednesday. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $55.20. The company has a quick ratio of 3.22, a current ratio of 3.29 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $17.16 billion, a P/E ratio of -6.04 and a beta of 1.32. The stock’s fifty day simple moving average is $37.86 and its 200-day simple moving average is $30.04.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, February 13th. The company reported ($2.11) EPS for the quarter, beating analysts’ consensus estimates of ($2.79) by $0.68. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The business had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. During the same quarter in the prior year, the company posted ($2.91) earnings per share. The firm’s revenue was down 33.2% on a year-over-year basis. Equities research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.